

Relative effects of LDL-C on ischemic stroke and coronary disease

A Mendelian randomization study

Elsa Valdes-Marquez, PhD, Sarah Parish, DPhil, Robert Clarke, FRCP, Traiani Stari, PhD, Bradford B. Worrall, MD, METASTROKE Consortium of the ISGC, and Jemma C. Hopewell, PhD

Neurology® 2019;92:e1176-e1187. doi:10.1212/WNL.0000000000007091

Correspondence

Dr. Hopewell
Jemma.Hopewell@
ndph.ox.ac.uk

Abstract

Objective

To examine the causal relevance of lifelong differences in low-density lipoprotein cholesterol (LDL-C) for ischemic stroke (IS) relative to that for coronary heart disease (CHD) using a Mendelian randomization approach.

Methods

We undertook a 2-sample Mendelian randomization, based on summary data, to estimate the causal relevance of LDL-C for risk of IS and CHD. Information from 62 independent genetic variants with genome-wide significant effects on LDL-C levels was used to estimate the causal effects of LDL-C for IS and IS subtypes (based on 12,389 IS cases from METASTROKE) and for CHD (based on 60,801 cases from CARDIoGRAMplusC4D). We then assessed the effects of LDL-C on IS and CHD for heterogeneity.

Results

A 1 mmol/L higher genetically determined LDL-C was associated with a 50% higher risk of CHD (odds ratio [OR] 1.49, 95% confidence interval [CI] 1.32–1.68, $p = 1.1 \times 10^{-8}$). By contrast, the causal effect of LDL-C was much weaker for IS (OR 1.12, 95% CI 0.96–1.30, $p = 0.14$; p for heterogeneity = 2.6×10^{-3}) and, in particular, for cardioembolic stroke (OR 1.06, 95% CI 0.84–1.33, $p = 0.64$; p for heterogeneity = 8.6×10^{-3}) when compared with that for CHD.

Conclusions

In contrast with the consistent effects of LDL-C-lowering therapies on IS and CHD, genetic variants that confer lifelong LDL-C differences show a weaker effect on IS than on CHD. The relevance of etiologically distinct IS subtypes may contribute to the differences observed.

From the Clinical Trial Service Unit and Epidemiological Studies Unit (E.V.-M., S.P., R.C., T.S., J.C.H.) and MRC Population Health Research Unit (S.P.), Nuffield Department of Population Health, University of Oxford, UK; and Departments of Neurology and Public Health Sciences (B.B.W.), University of Virginia School of Medicine, Charlottesville, VA.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was funded by the British Heart Foundation under the COAF Partnership.

METASTROKE Consortium of the ISGC coinvestigators are listed in appendix 2 at the end of the article.

The Article Processing Charge was funded by the British Heart Foundation under the COAF Partnership.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Glossary

CHD = coronary heart disease; **CI** = confidence interval; **HDL-C** = high-density lipoprotein cholesterol; **GLGC** = Global Lipids Genetics Consortium; **IS** = ischemic stroke; **LDL-C** = low-density lipoprotein cholesterol; **MR-Egger** = Mendelian randomization–Egger; **MR-PRESSO** = Mendelian randomization–Pleiotropy Residual Sum and Outlier; **OR** = odds ratio.

Stroke is a heterogeneous collection of clinically related but distinct disorders, with ischemic stroke (IS) representing 70%–90% of all strokes.^{1,2} Different IS subtypes have distinct underlying pathologies that likely reflect differences in the importance of underlying risk factors, such as hypertension and dyslipidemia, as well as in genetic determinants.^{3–6}

Randomized trials of statin therapy have demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) by 1 mmol/L reduces the risk of both IS and coronary heart disease (CHD) by about 20%.⁷ Other LDL-C-lowering therapies, such as ezetimibe and PCSK9 inhibitors, also yield comparable reductions in IS and CHD risk.^{8,9} In contrast, observational studies have found stronger effects of LDL-C on CHD than on IS,¹⁰ and potential heterogeneity in the effects of cholesterol on different IS subtypes.⁶ Therefore, further evidence is needed to determine whether LDL-C has comparable causal consequences for IS and CHD.

Mendelian randomization avoids many of the potential biases of observational studies, such as reverse causation and confounding. Mendelian randomization studies use genetic variants as instrumental variables that reflect lifelong differences in exposure to a risk factor, in order to examine its causal relevance for an outcome of interest. However, Mendelian randomization can be sensitive to pleiotropy, in which genetic variants are associated with multiple risk factors on different biological pathways. Mendelian randomization studies have been widely used to examine risk factors for CHD,^{11–14} but studies of IS have been limited.^{15–17}

The present Mendelian randomization study examines the causal relevance of LDL-C for IS and compares it with that for CHD.

Methods

Study populations

We obtained genome-wide association estimates for LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides from the Global Lipids Genetics Consortium (GLGC), based on up to 188,577 participants of European ancestry.¹⁸ The effects of these genetic variants on CHD were examined in the CARDIoGRAMPlusC4D Consortium including up to 60,801 CHD cases and 123,504 controls from 48 studies of predominantly European ancestry.¹⁹ Similarly, the effects on IS and IS subtypes were examined in METASTROKE, a collaboration of the International Stroke Genetics Consortium, which brings together genome-wide

data on a total of 12,389 IS cases and 62,004 controls of European ancestry from across 15 studies.²⁰ The majority of IS cases had brain imaging confirmation. Approximately 50% of cases had IS subtype information (2,365 cardioembolic, 2,167 large artery, and 1,894 small vessel stroke cases) based on Trial of Org 10172 in Acute Stroke Treatment classifications.²¹ Additional phenotype descriptions and details of individual studies, including data collection and genetic data quality control procedures, are reported elsewhere.²⁰

Standard protocol approvals, registrations, and patient consents

Each study included in the consortia was approved by an institutional review board, and all patients provided informed consent.

Selection of LDL-C associated genetic variants

We selected genetic variants with genome-wide significant ($p < 5 \times 10^{-8}$) associations with LDL-C in the GLGC meta-analysis and that were available in both the CARDIoGRAMplusC4D and METASTROKE datasets. Of these 2,243 genetic variants, we identified 99 independent variants ($r^2 < 0.01$ within $\pm 1,000$ kb) using the clumping method implemented in PLINK1.9 and 1,000 Genomes Project Phase 3 (EUR) reference population.^{22,23} Finally, to identify variants with LDL-C-specific lipid effects (and avoid pleiotropy through effects on other lipid pathways), we excluded the 37 variants with significant effects on HDL-C or triglycerides ($p < 0.0005$ based on Bonferroni correction for 99 variants). Hence, the primary analyses were restricted to the 62 variants with LDL-C-specific effects, with sensitivity analyses performed using all 99 variants that were independently associated with LDL-C (table e-1; doi.org/10.5061/dryad.8076h3r).¹⁸

Statistical analysis

Per-allele effects for LDL-C were extracted from GLGC and converted from the published SD units to mmol/L (1 SD unit equating to ~ 1 mmol/L). Per-allele effects of the variants on CHD were taken from CARDIoGRAMplusC4D¹⁹ and on IS (and IS subtypes) from METASTROKE.²⁰ To account for multiple testing, we used a predefined p value threshold of $p < 0.0005$ to indicate statistically significant associations of individual variants with risk of disease, and report all effects with respect to the LDL-C increasing allele unless otherwise stated. The percentage of variance explained in LDL-C was estimated by $2 \times (\text{effect on LDL-C in SD units})^2 \times \text{minor allele frequency} \times (1 - \text{minor allele frequency})$,²⁴ and power calculations for $p < 0.01$ were estimated from the variance explained and sample size.²⁵

Causal effects on disease outcomes per 1 mmol/L genetically higher LDL-C were estimated using the random-effects inverse-variance weighted method for summarized data (in which all genetic variants included are assumed to be valid instrumental variables).²⁶ To account for the multiple outcomes tested, a predefined p value threshold of $p < 0.01$ was used to indicate statistically significant causal associations. We conducted methodologic sensitivity analyses^{27,28} using the Mendelian randomization–Egger (MR-Egger) method (in which all genetic variants are permitted to be invalid instrumental variables, provided that the pleiotropic and risk factor effects of the variants are independently distributed—known as the instrument strength independent of direct effect assumption—and allows assessment of directional pleiotropic bias)^{29,30}; the weighted median method (in which 50% of the genetic variants are permitted to be invalid instrumental variables)³¹ and the multivariate method (in which potentially pleiotropic effects on HDL-C and triglycerides are allowed for by including terms for each lipid (table e-1; doi.org/10.5061/dryad.8076h3r) in the estimation of the causal effects, while fixing the intercept term as zero).³² The Mendelian randomization–Pleiotropy Residual Sum and Outlier (MR-PRESSO) method (which performs a pleiotropy residual sum and outlier test and allows detection and correction of pleiotropy by outlier removal) was also used to evaluate potential pleiotropy and identify outlying variants that were then excluded from the analyses.³³ Heterogeneity between the causal effects of individual variants, as well as comparisons between the causal effects of LDL-C on CHD vs IS (and IS subtypes), were tested using the Cochran Q statistic.²⁷ All statistical analyses were performed in SAS v9.3 or R v3.4.3.

Data availability

The data included in the reported analyses have been made publicly available (also see Acknowledgement for additional details on data access).

Results

Effects of LDL-C genetic variants on CHD, IS, and IS subtypes


The effects of the 62 individual genetic variants on LDL-C levels varied by 5-fold, ranging from 0.02 mmol/L to 0.10 mmol/L per allele (table e-1; doi.org/10.5061/dryad.8076h3r), and in combination explained about 4% of the variance in LDL-C. Despite limited power to detect risk associations with individual variants, 8 variants were associated with CHD and 2 with IS ($p < 0.0005$; table e-2; doi.org/10.5061/dryad.8076h3r). The effects of the 62 variants on IS and IS subtypes were consistently weaker than their effects on CHD (figure 1 and table e-3 and figures e-1 and e-2; doi.org/10.5061/dryad.8076h3r).

Causal effects of LDL-C on CHD, IS, and IS subtypes

Genetically determined LDL-C was associated with about a 50% higher risk of CHD per 1 mmol/L (odds ratio [OR] 1.49, 95% confidence interval [CI] 1.32 to 1.68; $p = 1.1 \times 10^{-8}$) but, by contrast, had no effect on IS (OR 1.12, 95% CI 0.96 to 1.30; $p = 0.14$). There were also no effects of genetically determined LDL-C on any of the individual subtypes of IS (figure 2).

The effect of LDL-C on IS was weaker than that on CHD (p for heterogeneity = 2.6×10^{-3}), and in particular on

Figure 1 Effects of genetic variants on coronary heart disease and ischemic stroke risk vs low-density lipoprotein cholesterol (LDL-C) levels



Figures are shown separately for (A) coronary heart disease and (B) ischemic stroke. Effects of the 62 individual genetic variants in the primary analysis are shown per LDL-C increasing allele.

cardioembolic stroke (p for heterogeneity = 8.6×10^{-3}), whereas the effects of LDL-C on large artery stroke and small vessel stroke were compatible with the magnitude of the effect observed for CHD (p for heterogeneity = 0.05 and 0.06, respectively; figure 2). Furthermore, given >99% power to detect a 30% increase in risk of IS at $p < 0.01$ (equivalent to the lower limit of the CI for CHD), these analyses can exclude a causal effect of LDL-C on total IS of the same magnitude as on CHD. However, given comparatively little power (<50%) to detect 30% causal effects for separate IS subtypes, comparable effects of LDL-C on CHD and particular IS subtypes cannot be excluded.


Sensitivity analyses

Sensitivity analyses were undertaken based on an instrument including 99 LDL-C-associated variants (of which 37 were also associated with HDL-C or triglycerides). This genetic instrument explained 11% of the variance in LDL-C, and was strongly influenced by the *TOMM40/APOE* locus, which represented ~2% of the variance in LDL-C. The estimates of the LDL-C causal effects on disease outcomes did not differ meaningfully from the primary analysis involving 62 variants with LDL-C-specific effects (figure e-3; doi.org/10.5061/dryad.8076h3r). However, they were slightly weaker, 1.05 (95% CI 0.96 to 1.15) vs 1.12 (95% CI 0.96 to 1.30) for IS per 1 mmol/L higher LDL-C, and showed greater

heterogeneity between individual variant causal effects than the primary analysis instrument ($p = 1.0 \times 10^{-5}$ vs $p = 2.5 \times 10^{-3}$). A similar pattern was also observed when comparing the causal effects of the different genetic instruments for CHD.

In the primary analyses, the LDL-C causal effect estimates for CHD and IS across genetic variants obtained by the inverse-variance weighted approach were consistent with those obtained by the weighted median and multivariate Mendelian randomization methods (table 1). There was no evidence of directional pleiotropy for either CHD (bias = -0.012, $p = 0.07$) or IS (bias = -0.014, $p = 0.08$). The causal estimates from the MR-Egger analysis were greater than those obtained by other methods. However, MR-Egger results should be interpreted with caution due to potential bias from outlying variants. The exclusion of outlying variants identified by MR-PRESSO reduced the causal estimates from MR-Egger, as well as the estimates of pleiotropic bias (bias = -0.006, $p = 0.23$ for CHD and bias = -0.008, $p = 0.26$ for IS). The heterogeneity between variants was also attenuated after making these exclusions ($p = 1.7 \times 10^{-9}$ vs 1.2×10^{-5} for CHD and $p = 2.5 \times 10^{-3}$ vs 0.18 for IS). Based on the 99-variant instrument, estimates were consistent across all the methods explored and there was no evidence of directional pleiotropy.

Figure 2 Effects of genetically determined low-density lipoprotein cholesterol (LDL-C) on vascular disease and ischemic stroke subtypes



Causal estimates are based on 62 variants associated with LDL-C in the primary analysis. Odds ratio and 95% confidence intervals (95% CIs) are provided for vascular disease (coronary heart disease and ischemic stroke) and ischemic stroke subtypes per 1 mmol/L higher genetically determined LDL-C.

Table 1 Sensitivity analyses estimating the causal effects of low-density lipoprotein cholesterol (LDL-C) on coronary heart disease and ischemic stroke

	Primary analyses (62 variants explaining 4% of the variance in LDL-C)		Sensitivity analyses (99 variants explaining 11% of the variance in LDL-C)	
	OR (95% CI) per 1 mmol/L higher LDL-C	<i>p</i>	OR (95% CI) per 1 mmol/L higher LDL-C	<i>p</i>
CHD				
Inverse-variance weighted Mendelian randomization	1.49 (1.32, 1.68)	1.1×10^{-8}	1.47 (1.37, 1.59)	4.5×10^{-17}
Inverse-variance weighted MR-PRESSO ^a	1.48 (1.35, 1.63)	4.8×10^{-11}	1.57 (1.48, 1.66)	8.8×10^{-27}
Weighted median Mendelian randomization	1.58 (1.41, 1.77)	6.1×10^{-11}	1.50 (1.38, 1.63)	4.4×10^{-16}
Multivariate Mendelian randomization	1.53 (1.34, 1.76)	5.0×10^{-8}	1.45 (1.34, 1.58)	6.2×10^{-15}
MR-Egger	1.88 (1.42, 2.50)	3.1×10^{-5}	1.51 (1.33, 1.71)	2.2×10^{-9}
MR-Egger MR-PRESSO ^a	1.68 (1.34, 2.13)	3.3×10^{-5}	1.70 (1.53, 1.89)	4.4×10^{-16}
Ischemic stroke				
Inverse-variance weighted Mendelian randomization	1.12 (0.96, 1.30)	0.14	1.05 (0.96, 1.15)	0.28
Inverse-variance weighted MR-PRESSO ^a	1.09 (0.84, 1.33)	0.17	1.05 (0.98, 1.12)	0.18
Weighted median Mendelian randomization	1.08 (0.89, 1.31)	0.42	1.01 (0.91, 1.13)	0.85
Multivariate Mendelian randomization	1.16 (0.98, 1.38)	0.09	1.06 (0.96, 1.16)	0.24
MR-Egger	1.48 (1.05, 2.10)	0.03	1.10 (0.96, 1.27)	0.17
MR-Egger MR-PRESSO ^a	1.28 (0.94, 1.74)	0.11	1.06 (0.94, 1.19)	0.34

Abbreviations: CHD = coronary heart disease; CI = confidence interval; MR-Egger = Mendelian randomization–Egger; MR-PRESSO = Mendelian randomization–Pleiotropy Residual Sum and Outlier; OR = odds ratio.

^a MR-PRESSO analyses were based on 10,000 simulations and a significance threshold of $p < 0.05$. In primary analyses, MR-PRESSO identified 5 outliers (rs1250229, rs4530754, rs579459, rs7770628, and rs7953150) for CHD and 2 (rs579459 and rs795310) for ischemic stroke. The exclusion of these variants reduced the horizontal pleiotropy (global test p value [observed residual sum of squares] from $p < 0.0001$ [211.82] to $p = 0.0001$ [117.60] for CHD and from $p = 0.003$ [100.26] to $p = 0.175$ [71.37] for ischemic stroke). The resulting instrumental variables continued to explain ~4% of the variance in LDL-C levels. In sensitivity analyses, MR-PRESSO identified 10 outliers (rs1250229, rs1531517, rs3125055, rs3184504, rs4530754, rs579459, rs7254892, rs7770628, rs7953150, and rs4970712) for CHD and 3 (rs3184504, rs579459, and rs795310) for ischemic stroke. The exclusion of these variants reduced the horizontal pleiotropy (global test p value [observed residual sum of squares] from $p < 0.0001$ [369.16] to $p < 0.0001$ [151.81] for CHD and from $p < 0.0001$ [173.36] to $p = 0.062$ [119.55] for ischemic stroke). The resulting instrumental variables for CHD and stroke explained ~9% and 11% of the variance in LDL-C levels, respectively. Tests for heterogeneity between causal estimates for CHD and ischemic stroke: inverse-variance weighted Mendelian randomization ($p = 2.6 \times 10^{-3}$), inverse-variance weighted MR-PRESSO ($p = 1.8 \times 10^{-4}$), weighted median Mendelian randomization ($p = 5.3 \times 10^{-4}$), multivariate Mendelian randomization ($p = 0.01$), MR-Egger ($p = 0.28$), and MR-Egger MR-PRESSO ($p = 0.15$).

Evidence of heterogeneity between the causal effects of LDL-C on CHD vs IS was consistent for all analysis approaches, with the exception of MR-Egger in the primary analyses and without exception for the 99-variant sensitivity analysis demonstrating weaker effects of genetically determined LDL-C on IS than on CHD (table 1).

Comparing observational, randomized, and genetic evidence

The effects of genetically determined LDL-C (per 1 mmol/L higher) on CHD and IS in the present study were similar to the corresponding effects reported for equivalent LDL-C changes in observational studies (figure 3).^{7,10} As observed in the genetic data, the observational associations of LDL-C with stroke were weaker than those with CHD ($p = 3.2 \times 10^{-8}$). In contrast, there was no such heterogeneity between the effects observed in the statin trials ($p = 0.20$).

Discussion

This Mendelian randomization study provides a large-scale comparison of the lifelong effects of LDL-C on risk of vascular disease, and demonstrates that genetically determined LDL-C has a weaker effect on IS than on CHD. Furthermore, these results were robust to the selection of LDL-C genetic variants used to estimate the causal effect as well as to different statistical approaches to Mendelian randomization analyses.

Observational evidence suggests that in addition to a differential effect of cholesterol on IS and hemorrhagic stroke, the effect of cholesterol on IS varies by subtype.^{6,34} In contrast, the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)³⁵ trial reported that atorvastatin effectively prevented recurrent stroke (independently of


the subtype of the previous stroke), but did not indicate that statins had differential effects on specific IS subtypes. However, genetic data from the SiGN study suggested a somewhat stronger effect of LDL-C on large artery stroke than on other IS subtypes.¹⁵ The present genetic study, which includes ~7,000 independent IS cases not previously reported in the SiGN study, showed a nonsignificant 12% higher risk on IS per 1 mmol/L genetically determined LDL-C, and relatively consistent effects of LDL-C across IS subtypes. However, this analysis had limited power to assess the causal effects of LDL-C on specific IS subtypes and on the compatibility with the effect on CHD. Furthermore, differences in the ethnicity of participants (SiGN included some non-European participants), in the instrumental variables used and clumping criteria (in which the present study was more stringent to avoid over-weighting), as well as unknown differences in vascular risk factor distributions may contribute to discrepancies between the studies. Thus, given the biological plausibility of differential effects of LDL-C on different IS subtypes (and previous evidence that genetic determinants of stroke are commonly subtype-specific²⁰), larger scale Mendelian randomization studies are still needed to clarify the lifelong

effects of LDL-C on etiologically distinct IS subtypes. In addition, IS subtype information is needed in large-scale randomized trials of LDL-modifying therapies to directly assess their effects on different subtypes of IS.

The analogy between Mendelian randomization and randomized clinical trials is commonly used. However, Mendelian randomization studies examine the lifelong cumulative effects of a risk factor, while clinical trials examine the short-term effect of a therapy. Consequently, the effect estimates from Mendelian randomization studies and randomized trials are not expected to be directly comparable. Mendelian randomization can assess the causal relevance of risk factors and help to anticipate relative effects of therapies on different disease outcomes, by studying genetic variants that have direct effects on a risk factor or that mimic therapeutic interventions, and by exploring the effects for one outcome relative to another, as in the present study.³⁶

Genetic variants that affect LDL-C levels via various biological pathways were combined in the analyses described to provide a strong instrument for LDL-C, under the

Figure 3 Effects of low-density lipoprotein cholesterol (LDL-C) on vascular disease in prospective studies, randomized statin trials, and genetic studies



Genetic effect of LDL-C on disease was estimated based on 62 variants associated with LDL-C (see primary analysis methods). Estimates from prospective studies are shown for usual levels of non-high-density lipoprotein cholesterol.¹⁰ Estimates from randomized statin trial for coronary heart disease are based on major coronary events (coronary death or nonfatal myocardial infarction).⁷ Estimates from genetic studies are taken from figure 2. CI = confidence interval.

assumption that LDL-C has consistent effects across all these mechanisms. However, genetic studies examining the effects of specific therapeutic targets that affect LDL-C and other biomarkers are also important for drug target evaluation. Recent studies examining instruments based on specific genes that mimic the effects of lipid-modifying therapies, such as *PCSK9*, *HMGCR*, and *NPC1L1*, have shown weaker effects on IS than on CHD, but also suggest that the different pathways involved may affect stroke subtypes differentially.^{15,37,38} A study of the combined effects of *CETP* and *HMGCR* has also suggested that the benefits of lowering LDL-C may depend on the reduction in apoB-containing lipoprotein particles.³⁹

The effects of LDL-C on IS were comparable to those on CHD in randomized trials of statin therapy, but were smaller for IS than for CHD in this genetic study (figure 3). Clinical trials of lipid-modifying therapies have typically recruited a high proportion of participants with, or at high risk of, coronary heart disease, and hence such patients are likely to have high levels of atherosclerosis. In the Cholesterol Treatment Trialists' meta-analysis of randomized statin trials, over 50% of participants had established CHD, and 70% had $\geq 10\%$ 5-year risk of a major vascular event.⁴⁰ By contrast, the majority of METASTROKE IS cases were recruited through acute stroke services or population studies and individuals thus are less likely to have comparable levels of atherosclerotic disease and risk. For example, in a hospital-based cohort of 4,033 stroke patients, only 10% had a history of myocardial infarction.⁴ Consequently, the relative contribution of different risk factors and the resulting distribution of IS subtypes may differ in the METASTROKE and randomized trial participants. A higher proportion of stroke cases in the METASTROKE meta-analysis may be due to non-atherosclerotic risk factors, such as atrial fibrillation, resulting in more cardioembolic strokes. By contrast, IS events in trials are more likely to be due to atherosclerosis resulting in a higher proportion of large artery strokes, for which therapeutic LDL-C lowering effects may have greater relevance. Such factors may also explain the stronger effects of LDL-C in randomized trials than in observational studies.

Etiologic differences in stroke may mean that even modest misclassification of IS could attenuate results, particularly given previous evidence indicating that lower LDL-C levels are associated with higher risks of hemorrhagic stroke.⁷ However, differential relevance of risk factors and pathways for CHD and IS as well as differences in patient characteristics between cohorts may explain some of the differences between IS and CHD observed in the present study.

Mendelian randomization analyses avoid many of the biases inherent in observational studies (e.g., confounding and reverse causation). However, such analyses rely on underlying assumptions, for example the validity of the instrument and the untestable MR-Egger INSIDE assumption, and can

also suffer from weak instrument bias. To explore the robustness of the analyses, the causal effect of LDL-C on disease outcomes was estimated by various Mendelian randomization methods that relax the instrumental variable validity assumption as well as after removal of outlying variants. The analyses conducted showed no meaningful differences. Furthermore, the estimates from this Mendelian randomization study were consistent with recent reports examining the individual causal effects of LDL-C on IS and on CHD.^{13,15,37,41–43}

This study suggests that LDL-C has a substantially weaker causal effect on IS than for CHD, a result that has potential implications for evaluation and development of therapeutic approaches. Additional large-scale genetic studies of IS, particularly with regard to specific IS subtypes and diverse ethnic populations, are needed to further elucidate these relationships. In addition, metabolomic studies may offer additional insights given that different LDL-C subparticles and their comparative pathogenicity for IS and different IS subtypes may be important given previous evidence of differences in the genetic determinants of the different particle sizes.⁴⁴

Acknowledgment

Summary results for LDL-cholesterol contributed by the Global Lipids Genetics Consortium, downloaded at csg.sph.umich.edu//abecasis/public/lipids2013/. Summary results for coronary heart disease contributed by CARDIOGRAMplusC4D investigators, downloaded at CARDIOGRAMPLUSC4D.ORG. Data from METASTROKE made available through a project proposal approved by the Steering Committee. The authors thank METASTROKE of the International Stroke Genetics Consortium collaborators for contributions. Acknowledgements for each of the METASTROKE collaboration studies are provided in the supplementary material.

Study funding

Supported by the Nuffield Department of Population Health. There was no commercial funder, but the study drew on expertise developed during research funded by commercial and academic funders. The Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, receives grants from the pharmaceutical industry for research conducted independently of all sources of funding (ctsu.ox.ac.uk/about-ctsu/documents/independent-research).

Disclosure

E. Valdes-Marquez reports no disclosures relevant to the manuscript. S. Parish reports grants from the Medical Research Council, UK, during the conduct of the study and a patent for a statin-related myopathy genetic test with royalties paid to the University of Oxford and the Medical Research Council from Boston Heart Diagnostics (with

any personal reward waived). R. Clarke reports no disclosures relevant to the manuscript. T. Stari contributed to this report while employed by University of Oxford; Traiani Stari is currently employed by Astellas. B. Worrall reports grant support from the NIH (U-01NS069208; U-01HG005160) and is Deputy Editor for *Neurology*[®]. J. Hopewell reports personal fellowship support from the British Heart Foundation (FS/14/55/30806). Go to Neurology.org/N for full disclosures.

Publication history

Received by *Neurology* April 16, 2018. Accepted in final form November 4, 2018.

Appendix 1 Authors

Name	Location	Role	Contribution
Elsa Valdes-Marquez, PhD	Clinical Trial Service Unit and Epidemiological Studies Unit, Department of Population Health, University of Oxford, UK	Author	Statistical analysis; drafting initial manuscript; revised the manuscript for intellectual content
Sarah Parish, DPhil	Clinical Trial Service Unit and Epidemiological Studies Unit and MRC Population Health Research Unit, Department of Population Health, University of Oxford, UK	Author	Study conception; drafting initial manuscript; revised the manuscript for intellectual content
Robert Clarke, FRCP	Clinical Trial Service Unit and Epidemiological Studies Unit, Department of Population Health, University of Oxford, UK	Author	Study conception; revised the manuscript for intellectual content
Traiani Stari, PhD	Clinical Trial Service Unit and Epidemiological Studies Unit, Department of Population Health, University of Oxford, UK	Author	Statistical analysis
Bradford B. Worrall, MD	Departments of Neurology and Public Health Science, University of Virginia School of Medicine, Charlottesville, VA	Author	METASTROKE data acquisition; revised the manuscript for intellectual content
Jemma C. Hopewell, PhD	Clinical Trial Service Unit and Epidemiological Studies Unit, Department of Population Health, University of Oxford, UK	Author	Study conception; METASTROKE data acquisition; drafting initial manuscript; revised the manuscript for intellectual content

Appendix 2 METASTROKE Consortium of the ISGC: Member roles

Members	Degrees	Affiliation
Agnieszka Slowik	MD, PhD	Department of Neurology, Jagiellonian University, Krakow, Poland
Albert Hofman	MD	Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, Netherlands
Ale Algra	MD, PhD	Department of Neurology and Neurosurgery, Utrecht Stroke Center, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Netherlands
Alex P. Reiner	MD	Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
Alexander S.F. Doney	PhD	Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee, UK
Andreas Gschwendtner	MD	Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität; and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
Andreea Ilinca	MD	Department of Clinical Sciences Lund, Neurology, Lund University, Sweden
Anne-Katrin Giese	MD	Department of Neurology, Massachusetts General Hospital, Harvard Medical School; and J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Boston, MA
Arne Lindgren	MD, PhD	Department of Clinical Sciences Lund, Neurology, Lund University; and Department of Neurology and Rehabilitation Medicine, Skåne University Hospital, Lund, Sweden
Astrid M. Vicente	PhD	Departamento Promoção da Saúde e Doenças Crônicas, Instituto Nacional de Saúde Dr Ricardo Jorge, Lisbon, Portugal
Bo Norrving	MD, PhD	Department of Clinical Sciences Lund, Neurology, Lund University; and Department of Neurology, Skåne University Hospital, Lund, Sweden
Børge G. Nordestgaard	MD, DMSc	Department of Clinical Biochemistry and The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital; and Faculty of Health Sciences, University of Copenhagen, Denmark
Braxton D. Mitchell	PhD, MPH	Department of Medicine, University of Maryland School of Medicine; and Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, MD
Bradford B. Worrall	MD, MSc	Departments of Neurology and Public Health Sciences, University of

Continued

Appendix 2 (continued)

Members	Degrees	Affiliation
		Virginia School of Medicine, Charlottesville, VA
Bruce M. Psaty	MD	Cardiovascular Health Research Unit, Department of Medicine, Department of Epidemiology, and Department of Health Services, University of Washington; and Kaiser Permanente Washington Health Research Institute, Seattle, WA
Cara L. Carty	PhD	Children's Research Institute, Children's National Medical Center; and Center for Translational Science, George Washington University, Washington, DC
Cathie L.M. Sudlow	BMBCh, MSc, DPhil, FRCP (Ed)	University of Edinburgh, UK
Christopher Anderson	MD, MMSc	Center for Genomic Medicine, Massachusetts General Hospital; J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Boston; and Program in Medical and Population Genetics, Broad Institute, Cambridge, MA
Christopher R. Levi	MBBS, B Med Sci, FRACP,	Sydney Partnership for Health Education Research & Enterprise (SPHERE), University of NSW (Sydney); and Priority Research Centre for Stroke & Brain Injury, University of Newcastle, Australia
Claudia L. Satizabal	PhD	Boston University School of Medicine, MA
Colin N.A. Palmer	PhD	Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee, UK
Dale M. Gamble	BS	Department of Neurology, Mayo Clinic, Jacksonville, FL
Daniel Woo	MD	University of Cincinnati College of Medicine, OH
Danish Saleheen	PhD	Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
E. Bernd Ringelstein	MD	Department of Neurology, University of Münster, Germany
Einar M. Valdimarsson	MD	Landspítali, University Hospital, Reykjavik, Iceland
Elizabeth G. Holliday	PhD	Public Health Stream, Hunter Medical Research Institute, New Lambton; and Faculty of Health and Medicine, University of Newcastle, Australia
Gail Davies	PhD	Department of Psychology and Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, UK
Ganesh Chauhan	PhD	Centre for Brain Research, Indian Institute of Science, Bangalore, India

Appendix 2 (continued)

Members	Degrees	Affiliation
Gerard Pasterkamp	MD, PhD	Laboratory of Experimental Cardiology, University Medical Center Utrecht, Netherlands
Giorgio B. Boncoraglio	MD	Department of Cerebrovascular Diseases, Fondazione IRCCS Istituto Neurologico "Carlo 85 Besta," Milan, Italy
Gregor Kuhlenbäumer	MD, PhD	Institute for Experimental Medicine, University of Kiel, Germany
Gudmar Thorleifsson	PhD	deCODE genetics/AMGEN, Reykjavik, Iceland
Guido J. Falcone	MD, ScD, MPH	Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, CT, USA; and Program in Medical and Population Genetics, The Broad Institute of Harvard and MIT, Cambridge, MA
Guillaume Pare	MD, MSc	Population Health Research Institute, McMaster University, Hamilton, Canada
Helena Schmidt	MD, PhD	Institute of Molecular Biology and Biochemistry, Medical University Graz, Austria
Hossein Delavaran	MD, PhD	Department of Clinical Sciences Lund, Neurology, Lund University; and Department of Neurology, Skåne University Hospital, Lund, Sweden
Hugh S. Markus	FRCP	Stroke Research Group, Division of Clinical Neurosciences, University of Cambridge, UK
Hugo J. Aparicio	MD	Department of Neurology, Boston University School of Medicine; and NHLBI's Framingham Heart Study, MA
Ian Deary	PhD	Department of Psychology and Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, UK
Ioana Cotlarciuc	PhD	Institute of Cardiovascular Research, Royal Holloway University of London, UK
Israel Fernandez-Cadenas	PhD	Neurovascular Research Laboratory, Vall d'Hebron Institute of Research, Neurology and Medicine Departments, Universitat Autònoma de Barcelona, Vall d'Hebrón Hospital, Barcelona; and Stroke Pharmacogenomics and Genetics, Fundació Docència i Recerca Mutua Terrassa, Terrassa, Spain
James F. Meschia	MD	Department of Neurology, Mayo Clinic, Jacksonville, FL
Jemma C. Hopewell	PhD	CTSU, Nuffield Department of Population Health, University of Oxford, UK

Appendix 2 (continued)

Members	Degrees	Affiliation
Jingmin Liu	MS	Fred Hutchinson Cancer Research Center, Seattle, WA
Joan Montaner	MD	Neurovascular Research Laboratory, Neurology and Medicine Departments, Universitat Autònoma de Barcelona and Institute of Research Vall d'Hebrón Hospital, Barcelona, Spain
Joanna Pera	MD, PhD	Department of Neurology, Jagiellonian University, Krakow, Poland
John Cole	MD	Department of Neurology, University of Maryland School of Medicine and Baltimore VAMC
John R. Attia	MD, PhD, FRACP, FRCPC	Hunter Medical Research Institute Public Health Research Program, Newcastle, Australia
Jonathan Rosand	MD, MSc	Center for Genomic Medicine, Massachusetts General Hospital; J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Boston; and Program in Medical and Population Genetics, Broad Institute, Cambridge, MA
Jose M. Ferro	MD, PhD	Serviço de Neurologia, Centro de Estudos Egas Moniz, Hospital de Santa Maria, Lisbon, Portugal
Joshua C. Bis	PhD	Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle
Karen Furie	MD	Department of Neurology, Massachusetts General Hospital, Boston
Kari Stefansson	MD, PhD	deCODE genetics/AMGEN; and Faculty of Medicine, University of Iceland, Reykjavik
Klaus Berger	MD	Institute of Epidemiology and Social Medicine, University of Münster, Germany
Konstantinos Kostulas	MD, PhD	Department of Neurology, Karolinska Institutet at Karolinska University Hospital, Huddinge, Sweden
Kristiina Rannikmae	MD, PhD	Centre for Clinical Brain Sciences, University of Edinburgh, UK
M. Arfan Ikram	MD, PhD	Department of Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands
Marianne Benn	MD, DMSc, PhD	Department of Clinical Biochemistry and The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, and Faculty of Health Sciences, University of Copenhagen, Denmark
Martin Dichgans	MD	Institute for Stroke and Dementia Research, Klinikum der Universität

Appendix 2 (continued)

Members	Degrees	Affiliation
		München, Ludwig-51 Maximilians-University, Munich, Germany
Martin Farrall	FRCPath	Department of Cardiovascular Medicine, University of Oxford, UK
Massimo Pandolfo	MD	Laboratory of Experimental Neurology, Brussels, Belgium
Matthew Traylor	PhD	Stroke Research Group, Division of Clinical Neurosciences, University of Cambridge, UK
Matthew Walters	MS	School of Medicine, Dentistry and Nursing at the University of Glasgow, UK
Michele Sale	PhD	Center for Public Health Genomics, University of Virginia, Charlottesville, VA
Michael A. Nalls	PhD	Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda; and Data Tecnica International, Glen Echo, MD
Myriam Fornage	PhD	Brown Foundation Institute of Molecular Medicine and Human Genetics Center, University of Texas Health Science Center at Houston
Natalie R. van Zuydam	PhD	Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee, UK
Pankaj Sharma	MD, PhD	Institute of Cardiovascular Research, Royal Holloway University of London, UK
Patricia Abrantes	PhD	Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal
Paul I.W. de Bakker	PhD	Department of Medical Genetics and Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Netherlands
Peter Higgins	MRCP	Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK
Peter Lichtner	PhD	Helmholtz Zentrum München and Technische Universität München, Institut für Humangenetik, Munich, Germany
Peter M. Rothwell	MD, PhD, FMedSci	Nuffield Department of Clinical Neurosciences, University of Oxford, UK
Philippe Amouyel	MD, PhD	INSERM U1167, Institut Pasteur de Lille; and Department of Public Health, Lille University Hospital, France
Qiong Yang	PhD	Boston University School of Public Health, MA
Rainer Malik	PhD	Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-51 Maximilians-University, Munich, Germany

Continued

Appendix 2 (continued)

Members	Degrees	Affiliation
Reinhold Schmidt	MD	Department of Neurology, Medical University of Graz, Austria
Robert Clarke	FRCP	CTSU, Nuffield Department of Population Health, University of Oxford, UK
Robin Lemmens	MD, PhD	Experimental Neurology, Department of Neurosciences, KU Leuven–University of Leuven; and Department of Neurology, VIB Center for Brain & Disease Research, University Hospitals, Leuven, Belgium
Sander W. van der Laan	PhD	Laboratory of Experimental Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Netherlands
Sara L. Pulit	PhD	Brain Center Rudolf Magnus, Department of Neurology, University Medical Center Utrecht, Netherlands
Sherine Abboud	MD, PhD	Laboratory of Experimental Neurology, Brussels, Belgium
Sofia A. Oliveira	PhD	Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
Solveig Gretarsdottir	PhD	deCODE genetics/AMGEN, Reykjavik, Iceland
Stephanie Debette	MD, PhD	INSERM U1219 Bordeaux Population Health Research Center; and University of Bordeaux, France
Stephen R. Williams	PhD	Department of Neurology, University of Virginia, Charlottesville, VA
Steve Bevan	PhD	School of Life Science, University of Lincoln, UK
Steven J. Kittner	MD, MPH	Department of Neurology, University of Maryland School of Medicine and Baltimore VAMC
Sudha Seshadri	MD	Department of Neurology, Boston University School of Medicine; and Framingham Heart Study, MA
Thomas Mosley	PhD	Division of Geriatrics, School of Medicine, and Memory Impairment and Neurodegenerative Dementia Center, University of Mississippi Medical Center, Jackson
Thomas W.K. Battey	BS	Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Center for Human Genetic Research, Massachusetts General Hospital, Boston
Turgut Tatlisumak	MD, PhD	Department of Clinical Neurosciences/Neurology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden
Unnur Thorsteinsdottir	PhD	deCODE genetics/AMGEN; and Faculty of Medicine, University of Iceland, Reykjavik

Appendix 2 (continued)

Members	Degrees	Affiliation
Vincent N.S. Thijs	MD, PhD	Stroke Division, Florey Institute of Neuroscience and Mental Health; and Austin Health, Department of Neurology, Heidelberg, Australia
W.T. Longstreth	MD	Departments of Epidemiology and Neurology, University of Washington, Seattle
Wei Zhao	MD, PhD	Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Wei-Min Chen	PhD	Center for Public Health Genomics, Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville
Yu-Ching Cheng	PhD	Department of Medicine, University of Maryland School of Medicine, Baltimore, MD

These members made contributions to the METASTROKE Consortium and to previously published METASTROKE genome-wide association meta-analyses, data collection, and wider scientific input. Jemma Hopewell was the Chair of the METASTROKE Consortium at the time of publication. Sudha Seshadri is the immediate past Chair of the METASTROKE Consortium.

References

- Markus HS. Stroke genetics. *Hum Mol Genet* 2011;20:R124–R131.
- O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet* 2016;388:761–775.
- Bevan S, Traylor M, Adib-Samii P, et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. *Stroke* 2012;43:3161–3167.
- Hauer AJ, Ruigrok YM, Algra A, et al. Age-specific vascular risk factor profiles according to stroke subtype. *J Am Heart Assoc* 2017;6:005090.
- Malik R, Traylor M, Pulit SL, et al. Low-frequency and common genetic variation in ischemic stroke: the METASTROKE collaboration. *Neurology* 2016;86:1217–1226.
- Schulz UG, Rothwell PM. Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. *Stroke* 2003;34:2050–2059.
- Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;376:1670–1681.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017;376:1713–1722.
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med* 2015;372:2387–2397.
- Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. *JAMA* 2009;302:1993–2000.
- Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. *J Am Coll Cardiol* 2015;65:1552–1561.
- Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. *J Am Coll Cardiol* 2012;60:2631–2639.
- Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J* 2015;36:539–550.
- Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease. *Eur Heart J* 2014;35:1917–1924.
- Hindy G, Engstrom G, Larsson SC, et al. Role of blood lipids in the development of ischemic stroke and its subtypes: a Mendelian randomization study. *Stroke* 2018;49:820–827.
- Hopewell JC, Clarke R. Emerging risk factors for stroke: what have we learned from Mendelian randomization studies? *Stroke* 2016;47:1673–1678.
- Larsson SC, Scott RA, Traylor M, et al. Type 2 diabetes, glucose, insulin, BMI, and ischemic stroke subtypes: Mendelian randomization study. *Neurology* 2017;89:454–460.
- Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet* 2013;45:1274–1283.
- Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet* 2015;47:1121–1130.

20. Traylor M, Farrall M, Holliday EG, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. *Lancet Neurol* 2012;11:951–962.
21. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993;24:35–41.
22. Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. *Nature* 2015;526:68–74.
23. Chang CC, Chow CC, Tellier LC, et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 2015;4:015–0047.
24. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. *Stat Med* 2016;35:1880–1906.
25. Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. *Int J Epidemiol* 2014;43:922–929.
26. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* 2013;37:658–665.
27. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. *Epidemiology* 2017;28:30–42.
28. Haycock PC, Burgess S, Wade KH, et al. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. *Am J Clin Nutr* 2016;103:965–978.
29. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512–525.
30. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur J Epidemiol* 2017;32:377–389.
31. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol* 2016;40:304–314.
32. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol* 2015;181:251–260.
33. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* 2018;50:693–698.
34. Bogiatzi C, Hackam DG, McLeod AI, Spence JD. Secular trends in ischemic stroke subtypes and stroke risk factors. *Stroke* 2014;45:3208–3213.
35. Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. *Stroke* 2009;40:1405–1409.
36. Ference BA. How to use Mendelian randomization to anticipate the results of randomized trials. *Eur Heart J* 2018;39:360–362.
37. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. *N Engl J Med* 2016;375:2144–2153.
38. Hopewell JC, Malik R, Valdes-Marquez E, Worrall BB, Collins R. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. *Eur Heart J* 2018;39:354–359.
39. Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. *JAMA* 2017;318:947–956.
40. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012;380:581–590.
41. Burgess S, Davey Smith G. Mendelian randomization implicates high-density lipoprotein cholesterol-associated mechanisms in etiology of age-related macular degeneration. *Ophthalmology* 2017;124:1165–1174.
42. Xu L, Borges MC, Hemani G, Lawlor DA. The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: a two-step, two-sample Mendelian randomisation study. *Diabetologia* 2017;60:2210–2220.
43. Zhu Z, Zheng Z, Zhang F, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat Commun* 2018;9:224.
44. Chasman DI, Pare G, Mora S, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. *PLoS Genet* 2009;5:e1000730.